Navigation Links
Pfizer Whistleblower Named Year's Most Influential Person In Business Ethics
Date:12/18/2009

WASHINGTON, Dec. 18 /PRNewswire-USNewswire/ -- John Kopchinski, the whistleblower whom Phillips & Cohen LLP represented in a successful, record-setting "qui tam" case against Pfizer Inc., has been named as the most influential person in business ethics for 2009.

Ethisphere, a think tank that focuses on business ethics, corporate social responsibility, anti-corruption and sustainability, compiles an annual list of the 100 most influential people in business ethics. The group named Kopchinski number one on its 2009 list.

A former sales representative for Pfizer, Kopchinski exposed the company's illegal sales and marketing campaign for the prescription painkiller Bextra for uses and in doses that endangered patients' health and lives. (See http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements531.asp)

Pfizer paid $1.8 billion in September to the government to settle Kopchinski's qui tam lawsuit and a related criminal charge. The company settled four other whistleblower lawsuits at the same time, bringing the total settlement to $2.3 billion. It was the largest healthcare fraud settlement ever and the largest criminal fine ever imposed in the U.S.

"John Kopchinski wasn't seen as a team player and ultimately lost his job at Pfizer," said Erika Kelton, a Washington, DC, attorney with Phillips & Cohen. "But the happy ending to his story and the recognition this honor bestows should give other whistleblowers hope."

Kopchinski "officially turned whistleblowing into big business," said Ethisphere. He received more than $70 million as a reward for the work he and his attorneys did on the Pfizer case. The False Claims Act requires the government to award whistleblowers a percentage of the funds the government recovers as a result of their qui tam cases.

Phillips & Cohen specializes in representing whistleblowers in cases involving fraud against the government, tax matters and securities violations. Cases brought by the firm's attorneys have recovered more than $5.3 billion in civil and criminal penalties for the government. For more information about whistleblowers and qui tam cases, see www.phillipsandcohen.com.

For more information about the Pfizer qui tam case and settlement, see http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements536.asp

SOURCE Phillips & Cohen LLP


'/>"/>
SOURCE Phillips & Cohen LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , VAE, January 20, 2017 ... stark gestiegenen Bedarf an Nothilfe   Die internationale ... Platz für Hilfsgüter zu schaffen   ... und Premierminister der VAE sowie Herrscher von ... der internationalen Stadt der Hilfe (International Humanitarian City IHC) ...
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical product ... as Chief Medical Officer. Dr Weinberg will be based in ... ... than 17 years as a pharmaceutical and biotech executive with experience ... course of his career, he has interfaced with the US Food ...
(Date:1/19/2017)... , Jan. 19, 2017 ... Summary GlobalData,s new report, "Germany Cataract Surgery Devices ... the Germany Cataract Surgery Devices market. The report provides ... and average prices (USD) within market segements - Phacoemulsification ... also provides company shares and distribution shares data for ...
Breaking Medicine Technology:
(Date:1/20/2017)... , ... January 20, 2017 , ... ... and its sugar-free alternative VW+ 002. The drinks have been produced in collaboration ... conditions to perform during your workout. , After a successful launch in Sweden ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how God ... is the creation of published author, Stephen Miller, who, for over ten long years has ... to him. Born in Trinidad and Tobago, he has been serving the Lord for over ...
(Date:1/20/2017)... ... ... is God’s Lighthouse”: a moving and colorful collection of prayers that reminds readers ... author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published works ... school and have many different titles,” Gaapf mentions about his different works. “I am ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... an On-demand E-learning system for Clinical and Regulatory education for Physicians, Physician ... on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , The ...
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO and ... name of their drug rehab center in Delray Beach, Florida has been changed from ... only stars such as Philip Seymour Hoffman and Chris Farley are dying from heroin ...
Breaking Medicine News(10 mins):